非奈利酮、肥胖与射血分数轻度降低/保留的心力衰竭:FINEARTS-HF预设分析
FINEARTS-HF预设分析纳入6001例NYHA II-IV级、LVEF≥40%的心衰患者,按WHO体重指数(BMI)分类评估非奈利酮疗效。基线BMI不影响非奈利酮对主要终点(心血管死亡和总心衰恶化事件)的获益(P交互=0.32),但BMI作为连续变量时高BMI者获益似更大(P交互=0.005)。
要点
- 非奈利酮对主要终点的获益在各BMI分类间一致(P交互=0.32)。
- BMI连续分析显示高BMI者非奈利酮获益可能更大(P交互=0.005)。
- 肥胖II-III级患者主要终点风险较正常体重者升高(率比1.26,95%CI 1.03-1.54)。
核心结论
- 在射血分数轻度降低/保留的心衰患者中,非奈利酮对临床事件和症状的获益在各基线BMI分类间一致,高BMI患者主要终点获益可能更大。
研究设计与样本
- FINEARTS-HF预设分析,纳入6001例NYHA II-IV级、LVEF≥40%、有结构性心脏病证据且利钠肽升高的心衰患者,随机接受非奈利酮或安慰剂。
- 按WHO BMI分类:体重不足/正常(<25.0 kg/m2,n=1306)、超重(25.0-29.9 kg/m2,n=1990)、肥胖I级(30.0-34.9 kg/m2,n=1546)、肥胖II级(35.0-39.9 kg/m2,n=751)、肥胖III级(≥40 kg/m2,n=395)。
- 主要终点为心血管死亡和总心衰恶化事件。
主要发现
- 与体重不足/正常者相比,肥胖II-III级患者主要终点风险更高(未调整率比1.26,95%CI 1.03-1.54)。
- 非奈利酮对主要终点的效应在各BMI分类间无交互作用(P交互=0.32)。
- BMI作为连续变量时,非奈利酮的获益随BMI升高而增大(P交互=0.005)。
- 总心衰恶化事件呈现相似模式;心血管死亡、全因死亡和KCCQ评分改善在各BMI间效应一致。
关键数值与推荐
- 主要终点率比:体重不足/正常0.80(95%CI 0.62-1.04),超重0.91(95%CI 0.72-1.15),肥胖I级0.92(95%CI 0.72-1.19),肥胖II-III级0.67(95%CI 0.50-0.89)。
临床怎么用
- 对于射血分数轻度降低/保留的心衰患者,无论基线BMI如何,均可考虑使用非奈利酮。
- 高BMI患者使用非奈利酮可能获得更大的主要终点获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity is associated with excessive adipocyte-derived aldosterone secretion, independent of the classical renin-angiotensin-aldosterone cascade, and mineralocorticoid receptor antagonists may be more effective in patients with heart failure (HF) and obesity. OBJECTIVES: This study sought to examine the effects of the nonsteroidal mineralocorticoid receptor antagonist finerenone compared with placebo, according to body mass index (BMI) in FINEARTS-HF (FINerenone trial to investigate Efficacy and sAfety superioR to placebo in paTientS with Heart Failure). METHODS: A total of 6,001 patients with HF with NYHA functional class II, III, and IV, a left ventricular ejection fraction of ≥40%, evidence of structural heart disease, and elevated natriuretic peptide levels were randomized to finerenone or placebo. BMI (kg/m2) was examined using World Health Organization categories, namely, underweight/normal weight (<25.0 kg/m2; n = 1,306); overweight (25.0-29.9 kg/m2; n = 1,990); obesity class I (30.0-34.9 kg/m2; n = 1,546); obesity class II (35.0-39.9 kg/m2; n = 751); and obesity class III (≥40 kg/m2; n = 395). The primary outcome was cardiovascular death and total worsening HF events. RESULTS: Data on baseline BMI were available for 5,988 patients (median: 29.2 kg/m2; Q1-Q3: 25.5-33.6 kg/m2). Compared with patients who were underweight/normal weight, those with obesity class II or III had a higher risk of the primary outcome (underweight/normal weight, reference; overweight, unadjusted rate ratio: 0.96 [95% CI: 0.81-1.15]; obesity class I: 1.04 [95% CI: 0.86-1.26]; obesity class II-III: 1.26 [95% CI: 1.03-1.54]). The effect of finerenone on the primary outcome did not vary by baseline BMI (underweight/normal weight, rate ratio: 0.80 [95% CI: 0.62-1.04]; overweight: 0.91 [95% CI: 0.72-1.15]; obesity class I: 0.92 [95% CI: 0.72-1.19]; obesity class II-III: 0.67 [95% CI: 0.50-0.89]; Pinteraction = 0.32). However, when BMI was examined as a continuous variable, the beneficial effect of finerenone seemed to be greater in those with a higher BMI (Pinteraction = 0.005). A similar pattern was observed for total worsening HF events. Consistent effects across baseline BMI were observed for cardiovascular and all-cause death and improvement in the Kansas City Cardiomyopathy Questionnaire scores. CONCLUSIONS: In patients with HF with mildly reduced/preserved ejection fraction, the beneficial effects of finerenone on clinical events and symptoms were consistent, irrespective of BMI at baseline, possibly with a greater effect on the primary outcome in patients with higher BMI. (FINEARTS-HF [FINerenone trial to investigate Efficacy and sAfety superioR to placebo in paTientS with Heart Failure]; NCT04435626).
引用
- Butt, Henderson, Jhund, et al. Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HF. J Am Coll Cardiol. 2024. PMID: 39665701. doi:10.1016/j.jacc.2024.10.111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。